In The News
Deepcure’s DC-9476 ameliorates rheumatoid arthritis scores
The bromodomain and extra terminal domain (BET) family of proteins, including BRD4, regulates the transcription of multiple proinflammatory and immunoregulatory genes. BRD4 is involved in immune-related disorders such as rheumatoid arthritis (RA).
AI in Drug Design: From Hype to Real-World Results
So, is AI washing adversely impacting the field of drug design? Less than one might suppose, suggests Kfir Schreiber, co-founder and CEO of DeepCure. He points out that emerging technologies in drug discovery often follow a familiar pattern: they start with great excitement, face a period of skepticism, and eventually gain renewed interest as they begin to deliver real results.
So, is AI washing adversely impacting the field of drug design? Less than one might suppose, suggests Kfir Schreiber, co-founder and CEO of DeepCure. He points out that emerging technologies in drug discovery often follow a familiar pattern: they start with great excitement, face a period of skepticism, and eventually gain renewed interest as they begin to deliver real results.
DeepCure to Present In Vivo Data Showing Its Selective BRD4 (BD2) Inhibitor DC-9476 is Superior to Etanercept in Rheumatoid Arthritis
DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced it will present data showing its selective BRD4 (BD2) inhibitor DC-9476 is superior to anti-TNF-α treatment in the collagen antibody-induced arthritis (CAIA) rheumatoid arthritis (RA) mouse model at the 11th International Conference on Autoimmunity: Mechanisms and Novel Treatments in Crete, Greece.
DeepCure to Present In Vivo Efficacy and Safety Data of BRD4 (BD2) Inhibitor DC-9476 for Macrophage Activation Syndrome at EMBO Conference
DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced it will present early safety and efficacy data for their BRD4 (BD2) Inhibitor DC-9476 for macrophage activation syndrome (MAS) at the European Molecular Biology Organization (EMBO) 2024 Conference, held September 24–27 in Germany.
How DeepCure taps reinforcement learning for first-in-class therapies
Boston-based DeepCure may be an AI-focused biotech, but it sets itself apart by focusing its AI-powered platform on historically challenging drug targets that have eluded traditional approaches. “While AI in drug discovery is often viewed as a means to accelerate and reduce costs, our focus at DeepCure is on achieving true novelty in drug development to address targets that have eluded researchers for decades,” said CEO Kfir Schreiber.
DeepCure links with Leeds Institute to bring AI-based RA drug to clinic
The partners will conduct a study using blood samples and joint biopsies from various patient subgroups, focusing on those resistant to current treatments.
DeepCure Announces Collaboration with Leeds Institute to Evaluate DC-9476 in Rheumatoid Arthritis
DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced a collaboration with one of the world’s premier research centers for rheumatoid arthritis (RA), the Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM). The collaboration will investigate DC-9476, a third-generation selective BRD4 (BD2) inhibitor, as a potential treatment for over a million patients worldwide with RA who do not respond well to current standard of care.
DeepCure Announces Selection of First AI-Generated Candidate DC-9476 for Autoimmune Diseases
DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced the selection of its first development candidate, DC-9476. DC-9476 is a third generation BRD inhibitor that is selective for the BD2 domain of Brd4, which is expected to enter clinical trials in 2025.
DeepCure Turns Complex Drug Designs into Testable Molecules with Robotic Synthesis Breakthrough
DeepCure, announced today that its Inspired Chemistry™ platform had achieved a breakthrough in chemical synthesis. In a demonstration study, the platform synthesized nirmatrelvir and 56 analogs in parallel using a robot-driven workflow.
DeepCure Closes $24M Funding Round Led by IAG Capital Partners
DeepCure announced today the closing of a $24.4 million Series A-1 financing led by IAG Capital Partners (IAG) with participation from the company’s current investors.
DeepCure Appoints Dr. Han Lim as Chief Business Officer
DeepCure announced today the appointment of Dr. Han Lim as Chief Business Officer (CBO). Dr. Lim will lead all business development, portfolio planning, and corporate strategy functions at the company.
New Company Enters AI Space with $40 Million in Hand – BioSpace
A Boston-based biotech company, DeepCure, announced the closing of its $40 million Series A financing round.
DeepCure scores $40M for AI-enabled drug discovery
DeepCure, developer of small molecule therapeutics using an AI-enabled drug discovery platform, raised $40 million in Series A funding.
DeepCure Closes $40M Series A Funding Led by Morningside Ventures – VentureBeat
Series A financing will catalyze growth and advance novel small molecule therapeutics pipeline across various disease indications.
DeepCure raised $40 million in Series A funding – Fortune
DeepCure, a Boston-based A.I. drug discovery company, raised $40 million in Series A funding. Morningside Ventures led the round and was joined by investors includingTLV Partners, Sapir Venture Partners, and Benon Group
AI upstart grabs $40M launch round – Endpoints
Boston AI-focused biotech DeepCure closed a $40 million Series A — adding more than five times the amount of money the company had before.
Drugmaker DeepCure Snares $40 Million – Wall Street Journal
DeepCure and other biotechs aim to accelerate drug discovery with artificial intelligence